Valbiotis S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALVAL.PA research report →
About the company
Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovascular diseases. The company's pipeline includes several key candidates: TOTUM-63, currently in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, undergoing Phase II trials to address hypercholesterolemia; and TOTUM-854, which is in Phase II/III clinical development for arterial hypertension.
- CEO
- Sebastien Peltier
- IPO
- 2017
- Employees
- 44
- HQ
- Périgny, FR
Price Chart
- Market Cap
- $20.45M
- P/E
- -1.73
- P/S
- 22.59
- P/B
- 2.89
- EV/EBITDA
- -1.81
- Div Yield
- 0.00%
- Gross Margin
- -128.84%
- Op Margin
- -1049.06%
- Net Margin
- -1040.55%
- ROE
- -100.77%
- ROIC
- -77.95%
- Revenue
- $905.00K · 417.14%
- Net Income
- $-9,417,000 · 6.06%
- EPS
- $-0.40 · 36.51%
- Op Income
- $-9,494,000
- FCF YoY
- 30.59%
- 52W High
- $1.30
- 52W Low
- $0.54
- 50D MA
- $1.00
- 200D MA
- $0.88
- Beta
- -0.20
- Avg Volume
- 172.97K
Get TickerSpark's AI analysis on ALVAL.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALVAL.PA coverage
Recent articles, reports, and earnings notes.
No research on ALVAL.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALVAL.PA report →Similar companies
Peers in the same neighborhood.